Tagged with M

Hong Kong Lawrence Wong outlines how reproductive medicine-focused Ferring Pharmaceuticals is serving the patients of Hong Kong as the city’s birth rates have plateaued, weighs in on why the establishment of a Hong Kong medicines regulator is a strategic imperative, and discusses how his firm is collaborating with colleagues in mainland China…

Belgium Janssen has the lofty aim of reaching USD 60bn dollars in sales by 2025, an 8bn increase on the 2021 figure, despite some high-profile losses of exclusivity and the spin-off of its consumer healthcare branch. This massive growth plan involves both existing products as well as new CAR-T and autoimmune…

Morocco Pfizer’s relationship with the North African Kingdom of Morocco dates back 57 years, and the US pharma giant is the only major multinational with a manufacturing presence in the country. The firm recently strengthened its commitment to Morocco – a nation of 37 million people which boasts Africa’s only free…

Americas Writing in the August edition of DIA’s Global Forum magazine, Silvia B. Bendiner of WESSX Inc. and Belkis Romeu call for greater regulatory collaboration between Latin American countries, building on an initiative created by Dr. Rafael Pérez Cristiá at the Cuban Regulatory Authority (CECMED).   The need for further regulatory…

China Writing in the August edition of DIA’s Global Forum magazine, Wen Yin of the Pfizer China R&D Center and Wanhe Deng of GSK China Investment look back on four years of China’s marketing authorization holder (MAH)-based regulatory system, including the opportunities it presents, and some of the implementation challenges.  …

Hong Kong Dr Brian CHUNG Hon-Yin, Chief Scientific Officer at the Hong Kong Genome Institute (HKGI) and Clinical Associate Professor at the University of Hong Kong (HKU) discusses the creation of the HKGI and the launch of its monumental undertaking, the Hong Kong Genome Project, the first of its kind in the…

Hong Kong Leveraging his 24-year career in Big Pharma, Howard Lin recently moved to set up healthcare and life science consultancy CL Consultancy in Hong Kong. Lin examines the opportunities and challenges for companies in Hong Kong and the Greater Bay Area region today; how the city acts as both a point…

UK The latest news from UK healthcare and life sciences, including the safety review of Novo Nordisk’s GLP-1 receptor agonists; VaxEquity’s grant to scale up RNA vaccine manufacturing; AstraZeneca/Quell Therapeutics cell therapy agreement and GSK’s acquisition of Bellus Health.   More evidence needed on Lilly’s weight loss drug, UK watchdog says…

Belgium There have been both ups and downs in AbbVie’s recent history. After proving its staying power with the celebration of its 10-year anniversary as an independent company spun off from Abbott, the American drugmaker faced a less happy turning point as its leading drug Humira came up against stiff competition…

China At a time when the country’s economy has fallen into a slump with the currency sinking to its lowest level in 16 years, Chinese giant Fosun Pharma continues to agressively advance its activities in everything from pharmaceuticals to medical devices and diagnosis to healthcare services. Through its multiple subsidiaries, as…

Belgium Representatives of Belgian associations for innovative pharma, generics and biosimilars, medtech, OTC, biotech, hospitals, and medical professionals share their key agenda priorities. These include where they feel that change is needed to drive better outcomes for their members as well as for the overall healthcare ecosystem.   Innovative Pharma: Building…

Europe Rainer Westermann, chairman of the Life Sciences Acceleration Alliance e.V. (LSAA), which lobbies on behalf of European venture capitalists in the life sciences space, critiques the draft EU Pharma Regulation from a VC perspective, arguing that the continent’s status as a medical innovation hub is at risk if the EU…